SC
IONS icon

Savant Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Savant Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$588K Sell
7,476
-985
-12% -$74.1K ﹤0.01% 1136
2026
Q1 		$635K Buy
8,461
+1,272
+18% +$100K ﹤0.01% 792
2025
Q4 		$569K Sell
7,189
-48
-0.7% -$3.61K ﹤0.01% 787
2025
Q3 		$473K Buy
7,237
+1,667
+30% +$81.4K ﹤0.01% 820
2025
Q2 		$220K Buy
+5,570
New +$182K ﹤0.01% 1112

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Savant Capital's IONS Position: Q2 2026 in Review

Savant Capital reduced its Ionis Pharmaceuticals (IONS) stake by 12% in Q2 2026, selling an estimated $74.1K and leaving 7,476 shares worth $588K. The position accounts for ﹤0.01% of the portfolio, ranked #1136.

Savant Capital first reported a position in IONS in Q2 2025 and has held it in 5 quarters since. The position peaked at $635K in Q1 2026. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Savant Capital held 7,476 shares of Ionis Pharmaceuticals worth $588K as of Q2 2026.
  • Savant Capital sold 985 Ionis Pharmaceuticals shares in Q2 2026, an estimated $74.1K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1136 holding.
  • Savant Capital first reported a position in Ionis Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Savant Capital's Ionis Pharmaceuticals position peaked at $635K in Q1 2026.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.